SRT 1720 (dihydrochloride)

SRT 1720 dihydrochloride is a selective and orally active activator of SIRT1 with an EC50 of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3[1].

Product Specifications

CAS Number

[2468639-77-0]

UNSPSC

12352005

Target

Autophagy; Sirtuin

Type

Reference compound

Related Pathways

Autophagy; Cell Cycle/DNA Damage; Epigenetics

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/srt-1720-dihydrochloride.html

Purity

99.19

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 2.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(NC1=C(C=CC=C1)C2=CN3C(SC=C3CN4CCNCC4)=N2)C5=NC6=C(N=C5)C=CC=C6.[H]Cl.[H]Cl

Molecular Formula

C25H25Cl2N7OS

Molecular Weight

542.48

References & Citations

[1]Milne JC et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29;450 (7170) :712-6|[2]Baur JA, et al. Are sirtuins viable targets for improving healthspan and lifespan?, Nat Rev Drug Discov. 2012 Jun 1;11 (6) :443-61|[3]Yao H, et al. SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice., J Clin Invest. 2012 Jun 1;122 (6) :2032-45.|[4]Gao D, et al. Activation of SIRT1 Attenuates Klotho Deficiency-Induced Arterial Stiffness and Hypertension by Enhancing AMP-Activated Protein Kinase Activity. Hypertension. 2016 Nov;68 (5) :1191-1199.|[5]Lahusen TJ, et al. SRT1720 induces lysosomal-dependent cell death of breast cancer cells. Mol Cancer Ther. 2015 Jan;14 (1) :183-92.